| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 37,483 | 45,981 |
| Stock-based compensation expense | 5,216 | 3,477 |
| Depreciation expense | 259 | 173 |
| (accretion) amortization on investments | 1,130 | 838 |
| Gain on sale of investments | 3 | 3 |
| Noncash rent expense | 2,340 | 1,549 |
| (gain) loss on sale of equipment | 24 | 23 |
| Prepaid expenses and other current assets | 98 | 573 |
| Other non-current assets | -132 | -88 |
| Accounts payable | -3,032 | -3,236 |
| Accrued expenses and other current liabilities | -1,996 | -532 |
| Non-current operating lease liabilities | -2,746 | -1,812 |
| Net cash provided by (used in) operating activities | 36,401 | 44,251 |
| Proceeds from sale of equipment | 24 | 23 |
| Proceeds from sales and maturities of investments | 86,083 | 62,583 |
| Purchases of investments | 128,123 | 113,212 |
| Net cash provided by (used in) investing activities | -42,016 | -50,606 |
| Proceeds from exercise of common stock options and espp, net of restricted stock surrendered for taxes | 50 | -84 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 50 | -84 |
| Net (decrease) increase in cash and cash equivalents | -5,565 | -6,439 |
| Cash and cash equivalents at beginning of period | 37,256 | - |
| Cash and cash equivalents at end of period | 31,691 | - |
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)